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INTRODUCTION
Emergent endotracheal intubation is a common procedure
performed for the stabilization of critically ill patients and
the majority of these patients will require an induction agent
for rapid-sequence intubation (RSI). Etomidate and midazo-
lam are the most popular drugs among the induction agents
(1).
Midazolam, however, can cause hypotension when used
in doses to produce sedation for intubation. It also has a broad
dose-response relationship that makes dosing inconsistent
and unpredictable (2, 3). The occurrence of hypotension is
associated with significant mortality and morbidity in criti-
cally ill patients (4, 5).
On the other hand, etomidate has become the induction
agent of choice for RSI due to its rapid onset of action and
recovery and minimal adverse cardiovascular and respiratory
effects (6, 7). However, etomidate is known to inhibit adrenal
mitochondrial hydroxylase activity, resulting in adrenocortical
dysfunction after administration by even though a single
bolus (8, 9). This disadvantage of etomidate can restrict its use
in patients prone to develop relative adrenal insufficiency
such as severe sepsis and septic shock (10-12).
The purpose of this study was to compare the incidence
of adrenal insufficiency and mortality between the patients
with severe sepsis and septic shock who received etomidate
as an induction agent during RSI and those who received
midazolam.
MATERIALS AND METHODS
In this retrospective study, we first identified 152 consec-
utive patients who had received cosyntropin stimulation test
(CST) and endotracheal intubation at Seoul National Uni-
versity Hospital between November 2004 and September
2006.
The medical records of these patients were reviewed and
we included the patients in this study if they met all of the
following criteria: 1) age older than 18 yr, 2) severe sepsis or
septic shock, 3) induction agents administered before emer-
gent endotracheal intubation, and 4) CST performed within
24 hr after the administration of the induction agents. Patients
were excluded if they had received corticosteroids or ketocona-
zole within 1 month prior the CST, or if they had an adrenal
or pituitary disorder. 
Severe sepsis and septic shock were defined according to
the American College of Chest Physicians/Society of Critical
Care Medicine Consensus Committee criteria (13). CST was
performed, as usual, using 250 μ g of tetracosactin (Synac-
thenTM, Ciba, England) and relative adrenal insufficiency was
defined as an increment of 9 μ g/dL or less after CST (14). 
Data collected included demographics, the dosage of induc-
tion agents and neuromuscular blockers, the time interval
between the induction agent administration and the CST,
Acute Physiology and Chronic Health Evaluation (APACHE)
II score on the 1st day of intensive care unit (ICU) admis-
sion, the results of CST, the length of ICU stay, hospital mor-
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Etomidate Should be Used Carefully for Emergent Endotracheal 
Intubation in Patients with Septic Shock
Etomidate and midazolam are the most popular drugs among the induction agents
for emergent endotracheal intubation. The purpose of this study was to compare
the incidence of adrenal insufficiency and mortality between the septic shock patients
who received etomidate (ETM group) and those who received midazolam (MDZ
group). Between November 2004 and September 2006, 65 patients were analyzed
in this study. The hospital mortality rate was 36% in the ETM group (n=25) and 50%
in the MDZ group (n=40), which was not statistically significant (p=0.269). The inci-
dence of relative adrenal insufficiency was significantly higher in the ETM group
than in the MDZ group (84% and 48%, respectively; p=0.003). On multivariate
analysis, the use of etomidate was the only significant factor affecting the incidence
of relative adrenal insufficiency (odds radio, 5.59; 95% confidence interval, 1.61-
19.4). In conclusion, we think that physicians who treat patients with septic shock
should be aware that etomidate can cause adrenal insufficiency, and should start
corticosteroids if etomidate is administered.
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tality, and 1-, 3-, and 6-month mortality.
Patients were divided into those who received etomidate
(ETM group) and those who received midazolam (MDZ
group). The Student’s t-test was used for comparisons of nor-
mally distributed continuous variables between two groups,
and binominal variables were analyzed with 
2 test or Fish-
er’s exact test, as appropriated. Predicting factors for mortal-
ity and relative adrenal insufficiency were evaluated by uni-
variate analysis. The factor(s) with a p value <0.2 by univari-
ate analysis would be taken to multivariate logistic regres-
sion analysis. Statistical analyses were carried out with SPSS
13.0 for Windows (SPSS Inc., Chicago, IL, U.S.A.) and a p
value <0.05 was considered statistically significant.
This study was approved by the Institutional Review Board
at Seoul National University Hospital.
RESULTS
Of the 152 consecutive patients who had CST and endo-
tracheal intubation, 56 were excluded. Fifty patients had
the CST done before or more than 24 hr after the adminis-
tration of the induction agents, and 6 patients had other types
of shock (5 cardiogenic shock and 1 hemorrhagic shock). 
Among the 96 patients met the inclusion criteria, 27
patients were excluded for having received corticosteroids,
and 4 patients had pituitary tumor. Finally 65 patients were
analyzed in this study.
Of the patients, 47 (72%) of patients were male and the
mean age of the patients was 64 yr. The mean dose of eto-
midate given was 0.3 mg/kg and that of midazolam 0.07
mg/kg. The time interval between the induction agent
administration and the CST was 10.6 hr and the mean of
APACHE II scores was 27. As summarized in Table 1, no
significant differences in the baseline characteristics except
the male-to-female ratio were found in between the two
groups (Table 1).
The overall hospital mortality rate was 45%, while the
hospital mortality rate predicted by the APACHE II score
was 61%. The hospital mortality rate was 36% in the ETM
group (n=25) and 50% in the MDZ group (n=40), which
was not statistically significant (p=0.269). There were no
significant differences in the 1-, 3-, and 6-month mortality
between the two groups. 
Twelve patients were failed to be intubated at the 1st att-
empt, and endotracheal intubation was attempted by 1st
and 2nd-year residents in all of 12 patients. The overall inci-
dence of relative adrenal insufficiency was 62%. The inci-
dence of relative adrenal insufficiency was significantly higher
in the ETM group than that in the MDZ group (84%, 48%
respectively; p=0.003) (Table 2). 
We performed univariate and multivariate analyses to iden-
tify significant factor(s) affecting the hospital mortality and
the relative adrenal insufficiency. The APACHE II score was
the only significant factor affecting the hospital mortality
(odds ratio [OR], 1.20; 95% confidence interval [CI], 1.06-
1.36) and the use of etomidate was the only significant fac-
tor affecting the incidence of relative adrenal insufficiency
(OR, 5.59; 95% CI, 1.61-19.4). 
*, Plus-minus values are means±SD.
ETM, patients who received etomidate as an induction agent; MDZ,
patients who received midazolam as an induction agent.
CST, cosyntrophin stimulation test; NA, not applicable.
Variables ETM
(n=25)
MDZ
(n=40)
p
value
Age (yr)  63.3±14.1 63.8±12.7 0.878
Male, n (%) 14 (56) 33 (83) 0.020
Body weight (kg) 59.0±17.2 54.0±11.2 0.163
Classification of sepsis (n)
Septic shock 25  38  0.887
Severe sepsis 0  2  NA
Site of infection, n (%)
Respiratory tract 15 (60) 30 (75) 0.583
Intraabdominal 4 (16) 6 (15) 0.913
Others 6 (24) 4 (10) 0.083
Pre-existing malignancy, n (%) 5 (20) 12 (30) 0.372
APACHE II score 27.5±6.4 26.4±5.6 0.479
Systolic blood pressure (mmHg) 95.1±17.2 93.8±19.8 0.794
Diastolic blood pressure (mmHg) 44.7±11.6 46.5±13.1 0.575
Mean arterial pressure (mmHg) 61.5±12.6 62.2±14.1 0.822
Heart rate (bpm) 99.8±23.6 99.6±27.7 0.980
Body temperature (°C) 36.7±1.4 36.7±1.3 0.869
Induction agent dose (mg/kg) 0.31±0.08 0.07±0.02 NA
Use of neuromuscular blocker,  21 (84) 35 (88) 0.691
n (%)
Glucocorticoids replacement  23 (92) 30 (75) 0.109
therapy, n (%)
Interval from induction agent 9.0±6.7 11.6±6.8 0.147
to CST (hr)
Baseline cortisol level (μ g/dL) 20.4±12.8 20.6±10.3 0.934
Table 1. Baseline characteristics of study patients by induction
agents*
*, Plus-minus values are means±SD.
ETM, patients who received etomidate as an induction agent; MDZ,
patients who received midazolam as an induction agent.
Variables ETM
(n=25)
MDZ
(n=40)
p
value
Hospital mortality, n (%) 9 (36) 20 (50) 0.269
1-month mortality, n (%) 8 (32) 17 (43) 0.397
3-month mortality, n (%) 10 (40) 21 (53) 0.326
6-month mortality, n (%) 13 (52) 23 (58) 0.664
Adrenal insufficiency, n (%) 21 (84) 19 (48) 0.003
ICU stay (day) 21.0±17.2 20.8±20.3 0.974
Intubation failure at 1st  0 12 (30) 0.002
attempt, n (%)
Table 2. Clinical outcomes by induction agents*990 T.Y. Kim, J.E. Rhee, K.S. Kim, et al.
DISCUSSION
Etomidate and midazolam are the most popular induc-
tion agents used during emergent endotracheal intubation,
and it is of great concern for physicians treating hemody-
namically unstable patients to determine which drug to use
when they require the induction agents to facilitate endo-
tracheal intubation. 
The aim of the present study was to compare the incidence
of adrenal insufficiency and mortality between the septic
shock patients who received etomidate and those who received
midazolam. As far as we know, there has been no report that
compared the clinical outcomes such as the incidence of rel-
ative adrenal insufficiency and mortality in the patients with
severe sepsis and septic shock who received etomidate and
midazolam, two most popular induction agents.
There are few studies that evaluated adrenal insufficiency
and hospital mortality between septic shock patients who
received etomidate and those who did not. Moreover, these
studies had significant drawbacks that they did not mention
the severity of septic shock and the time interval from admin-
istration of the induction agents to CST, and the use of sup-
plemental corticosteroids (15, 16). These factors can strong-
ly affect the incidence of adrenal insufficiency and hospital
mortality.
In accordance with previous studies, we found that 61.5%
of our patients had relative adrenal insufficiency (14, 17).
Also, the ETM group had a significantly higher incidence of
relative adrenal insufficiency than the MDZ group, which
reaffirms that etomidate can cause adrenocortical dysfunc-
tion (11, 15, 16).
In our study, there were no significant differences in hos-
pital mortality, 1-, 3-, and 6-month mortality between the
two groups even though the ETM group had a higher inci-
dence of relative adrenal insufficiency than the MDZ group,
which is consistent with previous studies (15, 16).
There are some explanations to these findings. First of all,
most of our patients received corticosteroids replacement
therapy, which may offset the detrimental effect of adrenal
insufficiency. Annane et al. demonstrated that in septic shock
patients with relative adrenal insufficiency, a 7-day treatment
with the combination of hydrocortisone and fludrocortisone
was associated with a significant reduction in short-term
and long-term mortality (19). In our study, 92% of ETM
group and 75% of MDZ group had corticosteroid replace-
ment therapy. Although it was not statistically significant
(p=0.109), the ETM group had an increased tendency to
take glucocorticoids.
Second, although the causal relationship between adrenal
insufficiency and mortality has remained open, there may
be a potentiality that adrenal insufficiency itself will not be
associated with an increased mortality. According to a recent
study on the adrenal function in patients with severe sepsis
and septic shock, adrenal insufficiency itself did not affect
the hospital mortality (17).
Last, adrenocortical dysfunction caused by etomidate may
be transient. Several studies suggest that a single dose of eto-
midate results in the suppression of adrenal function that
lasts at least 1 day in critically ill patients (11, 12, 18), while
one prospective randomized study showed that adrenocorti-
cal dysfunction resolves within 12 hr of a single bolus dose
of etomidate (9). All of the above might have contributed to
this finding; however, the authors think corticosteroids replace-
ment therapy would be the main cause that made little dif-
ference in mortality.
Another finding to be mentioned in our study was that
there was a significantly higher intubation failure rate in the
MDZ group than in the ETM group. The successful endo-
tracheal intubation depends on many factors such as patients’
airway anatomy, experience and competency of intubators, and
appropriate use of drugs and devices. 
In the present study, there were no significant differences
in body weight, age, and APACHE II score between the
patients who were successfully intubated or not at 1st attempt
(p=0.550 and 0.531, respectively). Interestingly, endotra-
cheal intubation was attempted by 1st and 2nd-year residents
and midazolam was administered in all of 12 patients who
failed to be intubated. 
As midazolam had been the most popular induction agent
and etomidate was introduced to the hospital merely a few
years ago, junior doctors would be apt to select midazolam
as a sedative of choice. We think the reason why the MDZ
group had a significantly higher intubation failure rate was
not that use of midazolam, by itself, affected the intubation
failure, but that more inexperienced doctors were included
in the MDZ group. We could not evaluate anymore the caus-
es of intubation failure because there was not enough of the
detailed information about each intubation.
This study had several limitations. It was performed in a
single tertiary hospital and had a retrospective study design.
The small sample size may account for the absence of statisti-
cally significant difference in some of variables including
hospital mortality.
Our study showed that etomidate used in patients with
severe sepsis and septic shock causes adrenocortical dysfunc-
tion, although the mortality was not affected. 
In conclusion, physicians who treat patients with severe
sepsis and septic shock should be aware that the use of eto-
midate significantly increases the incidence of relative adrenal
insufficiency, and it would be safer to start corticosteroid
replacement therapy once etomidate is administered in these
patients.
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